BIODESIX INC - BDSX STOCK NEWS

Biodesix, focused on lung disease diagnostic solutions, announced a webinar on April 26, 2021, addressing biomarkers and risk assessment in lung nodule management. Led by Dr. Susan Garwood, the session aims to improve identification of malignant lung nodules and enhance referral pathways for patients based on blood-based biomarker testing. Dr. Garwood emphasized the importance of education on risk assessment for monitoring low-risk patients while prioritizing high-risk cases for specialist referral. Biodesix continues to innovate with non-invasive tests for lung disease, including the Biodesix Lung Reflex and Nodify Lung strategies.

Biodesix, Inc. (Nasdaq: BDSX) announced the presentation of three clinical study abstracts at the 2021 AACR Annual Meeting, emphasizing blood-based proteomic testing's potential to enhance cancer treatment decisions. Abstract #520 explores how the Primary Immune Response (PIR) test can predict immune-related adverse events (irAEs) in non-small cell lung cancer (NSCLC) patients undergoing immunotherapy. Abstract #673 discusses PIR's ability to stratify patients for immune checkpoint inhibitor therapy, while Abstract #662 highlights the VeriStrat test's effectiveness in monitoring disease progression in advanced NSCLC patients.

Biodesix (Nasdaq: BDSX) announced that the U.S. Patent and Trademark Office has issued two new patents enhancing its blood-based immunotherapy diagnostics. The first patent, U.S. Patent 10,950,348, enables classification of lung cancer patients based on their likely response to immunotherapies. The second patent, U.S. Patent 10,870,891, covers a method for detecting fragmented RNA in blood, improving the precision of diagnostics. These advancements are expected to boost patient treatment personalization and support ongoing biopharma collaborations.

Biodesix (NASDAQ: BDSX) announced the closure of a $30 million term loan maturing March 1, 2026. The funds were primarily utilized to repay $25.9 million from an existing term loan with Innovatus, enhancing the company's liquidity with approximately $4 million reserved for corporate purposes. This refinancing aims to improve financial flexibility, reduce cash interest costs, and support the growth of Biodesix's commercial organization and clinical pipeline. CEO Scott Hutton expressed confidence in the company's plans, highlighting lender trust amid ongoing pandemic disruptions.

Biodesix, a leader in lung disease diagnostics, reported strong financial results for Q4 and FY 2020, showcasing a record revenue of $45.6 million, an 86% increase from 2019. The fourth quarter alone generated $27.0 million, a 194% growth from Q3 2020, driven largely by COVID-19 testing revenue of $21.4 million. The company strengthened its balance sheet with $62.1 million in cash by year-end. CEO Scott Hutton emphasized the company's strategic focus on lung diagnostics while expanding its COVID-19 testing capabilities, forecasting continued growth into 2021.

Biodesix (BDSX) will announce its financial results for Q4 and the year ended December 31, 2020, after market close on March 16, 2021. The management will host a conference call at 4:30 PM ET the same day to discuss the results and provide a business update. Biodesix focuses on lung disease diagnostics, offering innovative solutions like the Lung Reflex strategy and Nodify Lung testing. The company has launched diagnostic tests in response to COVID-19, enhancing its portfolio. Investors should tune in for insights on performance and future plans.

Biodesix, Inc. (Nasdaq: BDSX) announced that CEO Scott Hutton was named one of the Top 25 Biotech CEOs of 2021 by The Healthcare Technology Report. Hutton's leadership during the pandemic, including efforts to mitigate COVID-19 infection rates, has been pivotal for the company. Under his guidance since 2018, Biodesix has seen significant advancements, including responses to COVID-19 and a successful Initial Public Offering in October 2020. Hutton credits the achievement to the dedication of the entire Biodesix team in overcoming challenges during this period.

Biodesix (Nasdaq: BDSX) has partnered with Chicago Public Schools (CPS) to provide COVID-19 testing for teachers and staff. The program, initiated in January, includes rapid antigen tests and confirmatory Droplet Digital PCR (ddPCR) testing. Biodesix, experienced in testing large groups, aims to enhance public health for educators. Staff will undergo testing at least twice monthly, with increased frequency for those in high-risk areas. CPS is the third largest U.S. school district, serving over 350,000 students.

Biodesix, a diagnostic solutions leader focused on lung disease, announced participation in two major conferences. The BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference will take place from February 17-19, 2021, featuring a fireside chat on February 17 at 4:00 PM ET. Additionally, Biodesix will participate in the LifeSci Partners Precision Oncology Day on the same date, hosting a panel on diagnostic sequencing at 12:00 PM ET. Biodesix continues to innovate in diagnostic testing, leveraging AI to enhance patient care.